Vertex Pharmaceuticals Reports Interim Data for Hepatitis C Treatment

Vertex provided positive interim results for a Phase IIa trial of telaprevir in treating patients with the hepatitis C virus (HCV).

The study explored the safety and antiviral activity of a twice-daily dosing regimen of telaprevir in combination with peg-IFN and RBV as compared with a three-times daily regimen. An analysis showed that both dosing arms had more than 80 percent of patients with undetectable HCV RNA levels at weeks four and 12, Vertex said.

The company is studying telaprevir in multiple clinical trials. A complete analysis of the Phase IIa trial will be performed after the study’s conclusion next year.